Grant: Operating Grant - Priority Announcement: Ethics
McGill University
$150,000.00
Justifying Translational Clinical Trials: An Ethical Analysis of Risk, Design, and Prediction
EF 2009-10
Résumé
Patients who enroll in "translational clinical trials" are the first human beings to receive a drug after it has been tested in animals. Because these trials involve a high degree of uncertainty about risk and benefit, they present a number of unresolved ethical challenges. This grant proposes to address four fundamental ethical issues in translational clinical trials. First, at what point during a drug's development are its risks justified by the potential therapeutic benefits for patients who enroll in studies? Second, are there reasons other than protecting patient welfare for performing stringent scientific and safety review of translational clinical trials? Third, what kinds of scientific benefits can justify a translational trial in circumstances where giving novel drugs is not therapeutically justified? Fourth, what are the most ethically sound ways of making predictions about benefit and risk when knowledge about a drug's properties is at its most uncertain?
Programme
Operating Grant - Priority Announcement: Ethics
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
196499
Name
Kimmelman Jonathan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Humanities, Social Sciences, Law & Ethics in Health
Projecttitle
Justifying Translational Clinical Trials: An Ethical Analysis of Risk, Design, and Prediction
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Ethics
Keyworddelim
Bioethics; Phase 1 Trials; Research Ethics; Risk; Scientific Value; Translational Research
Abstract
Patients who enroll in "translational clinical trials" are the first human beings to receive a drug after it has been tested in animals. Because these trials involve a high degree of uncertainty about risk and benefit, they present a number of unresolved ethical challenges. This grant proposes to address four fundamental ethical issues in translational clinical trials. First, at what point during a drug's development are its risks justified by the potential therapeutic benefits for patients who enroll in studies? Second, are there reasons other than protecting patient welfare for performing stringent scientific and safety review of translational clinical trials? Third, what kinds of scientific benefits can justify a translational trial in circumstances where giving novel drugs is not therapeutically justified? Fourth, what are the most ethically sound ways of making predictions about benefit and risk when knowledge about a drug's properties is at its most uncertain?
Competitiondate
200909
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kimmelman, Jonathan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~